Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer

Inclusion Criteria

• •Histologically or cytologically confirmed metastatic breast adenocarcinoma
• •No HER2 overexpression or gene amplification
• •Absent or low ER or PR expression
• •No previous therapy for metastatic breast cancer is allowed
• •Age 18-75 years
• •Measurable disease as defined by the presence of at least one measurable lesion (except bone metastases, ascites or pleural effusions)
• •Performance status (WHO) 0-2
• •Adequate liver (serum bilirubin \<1.5 times the upper normal limit, AST and ALT \<2.5 times the upper normal limit in the absence of demonstrable liver metastases, or \<5 times the upper normal limit in the presence of liver metastases)
• •adequate renal function (serum creatinine \<1.5 times the upper normal limit)
• •bone marrow (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109 /L)
• •No radiation of measurable disease (except brain metastases)
• •No progressive brain metastases according to clinical or radiological criteria
• •No brain metastases without prior radiation therapy
• •Written informed consent